

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

AMAG PHARMACEUTICALS, INC.,)	
)	
Plaintiff,)	
)	Civil Action No. 3:16-cv-01508-PGS-LHG
v.)	
)	
SANDOZ INC.,)	CONFIDENTIAL
)	FILED UNDER SEAL
Defendant.)	
)	

STIPULATION AND ORDER

WHEREAS Defendant Sandoz Inc. (“Sandoz”) submitted Abbreviated New Drug Application (“ANDA”) No. 206604 to the U.S. Food and Drug Administration (“FDA”) seeking approval for Ferumoxytol Injection, 30 mg/mL, 17 mL single-use vials (“Sandoz ANDA Product”) prior to the expiration of, *inter alia*, United States Patent Nos. 6,599,498 B1 (“the ’498 patent”), 7,553,479 B2 (“the ’479 patent”), 7,871,597 B2 (“the ’597 patent”), 8,591,864 B2 (“the ’864 patent”), and 8,926,947 B2 (“the ’947 patent”), which are listed in the electronic version of FDA’s publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (“Orange Book”), in connection with Feraheme®;

WHEREAS Plaintiff AMAG Pharmaceuticals, Inc. (“AMAG”) filed the above-captioned action for alleged infringement of the ’498, ’479, ’597, ’864 and ’947 patents;

WHEREAS the ’479, ’597, ’864 and ’947 patents expire March 8, 2020, and the ’498 patent expires June 30, 2023;

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

NOW THEREFORE, IT IS HEREBY STIPULATED, AGREED, AND ORDERED that:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6. [REDACTED]

[REDACTED]

7. This stipulation shall not be used in any other proceeding or litigation, except to enforce its terms.

8. This Court retains jurisdiction to enforce or supervise performance under this Order.

Dated: March 9, 2018

By: /s/ Michael Patunas
Michael Patunas
PATUNAS LAW LLC
24 Commerce Street, Suite 606
Newark, NJ 07102
Tel.: (973) 396-8740
mpatunas@patunaslaw.com

By: /s/ Christina L. Saveriano
Eric I. Abraham
Christina L. Saveriano
HILL WALLACK LLP
21 Roszel Road
Princeton, New Jersey 08540
(609) 924-0808
eia@hillwallack.com
csaveriano@hillwallack.com

OF COUNSEL:

Elizabeth J. Holland
Calvin E. Wingfield Jr.
Natasha G. Daughtrey
Tyler Doh
Tiffany Mahmood
Shaun de Lacy
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
(212) 813-8800

OF COUNSEL:

William A. Rakoczy
Deanne M. Mazzochi
Tara M. Raghavan
Conly S. Wythers
**RAKOCZY MOLINO MAZZOCHI
SIWIK LLP**
6 West Hubbard Street Suite 500
Chicago, Illinois 60654
(312) 222-6301

Attorneys for Defendant Sandoz Inc.

Daryl L. Wiesen
Srikanth K. Reddy
Sundar Subramanyam
GOODWIN PROCTER LLP
100 Northern Ave
Boston, MA 02210
(617) 570-1000

*Attorneys for Plaintiff AMAG
Pharmaceuticals, Inc.*

SO ORDERED:

PETER G. SHERIDAN, U.S.D.J.